Project Grant R01AG095773
Award Date 9/15/25
Completion Date 5/31/30
Dollars Obligated $849K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $781,008.00 to investigate the role of tRNA modifications in regulating mitochondrial function and the mitochondrial proteome in Alzheimer's disease and related disorders (AD/ADRD). The research aims to identify genetic mutations in mitochondrial DNA, tRNA genes, and genes encoding the mitochondrial proteome that are associated with AD status, using large-scale whole genome sequencing data from...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $848,286 to the University of South Florida to conduct research on the role of N6-methyladenosine (m6A) RNA modifications in Alzheimer's disease (AD). The key objectives are to: 1) Create a high-resolution map of m6A sites in the brains of older adults, 2) Identify specific m6A alterations associated with AD and its clinical/pathological features, and 3) Elucidate how m6A dysregulation may...
- The National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), awarded a $805,573 project grant to The Regents of the University of California, San Francisco to investigate the impact of m6A RNA modifications in Alzheimer's disease and related tauopathies. The grant will support research to uncover changes in m6A RNA modifications and their functional consequences in post-mortem brain tissue from subjects with Alzheimer's disease and other tauopathies,...
- The Brigham & Women's Hospital Inc. was awarded a $3,672,952 Project Grant from the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) to investigate the role of tRNA-derived fragments (TRFs) in tau pathology associated with Alzheimer's disease (AD) and related tauopathies. The research aims to characterize the small RNA landscape, with a focus on TRFs, at different stages of AD pathology and examine the RNA binding capacity of tau variants. The...
- This $784,596 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Northeastern University supports comprehensive proteogenomic profiling of aberrant and mis-processed proteins in Alzheimer's disease and tauopathy models. The project aims to develop a proteogenomic pipeline to globally characterize disease-associated proteins with amino acid substitutions, alternative isoforms, post-translational modifications, and proteolytic cleavages across multiple brain...
- This federal Project Grant award of $839,933 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to investigate the role of N6-methyladenosine (m6A) RNA modifications in microglial dysfunction and Alzheimer's disease (AD) pathogenesis. The project aims to systematically map m6A modification landscapes in microglia isolated from human brain tissue and human induced pluripotent stem cell-derived microglial models. The researchers will also use CRISPR-based...
- This federal Project Grant award for $528,876, provided by the National Institute on Aging (CFDA 93.866 Aging Research), supports research to investigate the cis- and trans-genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease (AD) and AD-related dementias (ADRD). The key goals of the project are to: Estimate genome-wide cis- and trans-acting quantitative trait loci (QTLs) effects for transcriptome-wide genes and proteome-wide proteins across 4 brain...
- This $3,360,074 federal Project Grant was awarded on September 15, 2025 by the National Institute on Aging (NIA) under the Aging Research grant program (CFDA 93.866). The grant is funding research led by the University of Pennsylvania to develop short RNA therapeutics that can combat TDP-43 proteinopathy, a key pathological feature of several devastating neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia. The research aims to...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to elucidate the role of RNA modification, specifically N6-methyladenosine (m6A), in the pathogenesis of Alzheimer's disease (AD) and related tauopathies. The total award amount is $745,092 over the project period from January 1, 2025 to November 30, 2029. The key objectives are to: 1) decode the epitranscriptomic profiles impacted by tau pathology using m6A DART-seq; 2) determine the role of RNA...
- This Project Grant award for $466,125, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), supports research to analyze the effects of Alzheimer's disease on subcellular transcriptome dynamics and mitonuclear coordination in neuronal soma and projections. The research, conducted by Harvard Medical School, will use a novel technique called Subcellular Timelapse-Seq (STL-Seq) to simultaneously quantify the kinetic rates of transcription, nuclear export, ribosome...